Lefebvre G, Lacombe C
Service de Gynécologie-Obstétrique, Université Paris VI, CHU Pitié-Salpêtrière.
Rev Fr Gynecol Obstet. 1991 Feb 25;86(2 Pt 2):206-8.
We realized a double-blind randomized study in 26 pregnant with clinical symptoms of lower limbs venous insufficiency. Both groups were similar and received either (n = 12) troxerutine (4 g/day) or placebo (n = 14), during 30 days. Evaluation at J0 and J30 was both clinical and rheological by mean of Myrenne aggregometer. After blood shear rate of 600 s-1, two parameters were determined: M after roughly stopping shear rate, M1 after diminishing to shear rate of 3 s-1. Results exhibited steady values in patients receiving troxerutine while a significant increasing values in patients receiving placebo for the two parameters M and M1. That result in erythrocyte antiaggregating action of troxerutine, hence lowering viscosity action, in venous insufficiency during pregnancy.
我们对26名有下肢静脉功能不全临床症状的孕妇进行了一项双盲随机研究。两组情况相似,在30天内,一组(n = 12)接受曲克芦丁(4克/天),另一组(n = 14)接受安慰剂。在第0天和第30天通过Myrenne血液凝集仪进行临床和流变学评估。在600 s-1的血液剪切速率后,测定两个参数:大致停止剪切速率后的M,剪切速率降至3 s-1后的M1。结果显示,接受曲克芦丁的患者中这两个参数M和M1的值稳定,而接受安慰剂的患者中这两个参数的值显著增加。这表明曲克芦丁在孕期静脉功能不全中具有红细胞抗聚集作用,从而具有降低粘度的作用。